Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655420 · ClinicalTrials.gov registry record
Patient Reported Outcomes With LASIK: PROWL-2
A clinical trial of Laser in Situ Keratomileusis, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT01655420 is a study of Laser in Situ Keratomileusis that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 300 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT01655420, a study of Laser in Situ Keratomileusis, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study evaluates a questionaire designed to measure satisfaction and ophthalmic-related quality of life (QoL) of 300 civilian participants prior to and three months following state-of-the-art laser in situ keratomileusis (LASIK).
Conditions Studied
Interventions
- PROCEDURE LASIK
Study Locations (5)
California
- Stanford University School of Medicine - Stanford
Indiana
- 20/20 Institute - Indianapolis
Kansas
- Durrie Vision - Overland Park
Maryland
- Johns Hopkins University School of Medicine - Baltimore
South Dakota
- Vance Thompson Vision - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655420
The ClinicalTrials.gov registry entry for NCT01655420 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Laser in Situ Keratomileusis appearing as the primary indexed condition, and to 1 intervention - of which LASIK is the first listed.
NCT01655420 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Indiana, Kansas.
Frequently Asked Questions
What is clinical trial NCT01655420 about?
NCT01655420 is a clinical study titled "Patient Reported Outcomes With LASIK: PROWL-2". This study evaluates a questionaire designed to measure satisfaction and ophthalmic-related quality of life (QoL) of 300 civilian participants prior to and three months following state-of-the-art laser in situ keratomileusis (LASIK).
What is the current status of trial NCT01655420?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2012-07.
What conditions does trial NCT01655420 study?
This clinical trial studies the following conditions: Laser in Situ Keratomileusis.
What interventions are being tested in trial NCT01655420?
The interventions under investigation include: LASIK (PROCEDURE).
Who is sponsoring clinical trial NCT01655420?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01655420 being conducted?
This trial has 5 study locations across California, Indiana, Kansas, Maryland, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.